Brief: Clover Biopharmaceuticals's Unit Enters Collaboration Agreement With Jiangsu Ascentage Pharma
09/12/2021 15:19
Dec 9 (Reuters) - Clover Biopharmaceuticals Ltd 2197.HK :
* UNIT ENTERED INTO A COLLABORATION AGREEMENT WITH JIANGSU
ASCENTAGE PHARMA
* DEAL TO EXPLORE TREATMENT OPTIONS AND ALTERNATIVES TO
SURGERY
FOR PATIENTS SUFFERING FROM PERITONEAL CARCINOMATOSIS
Source text for Eikon: ID:nHKS3LdvCQ
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune